3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
4
NIH
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
302
Carboplatin
230
Cisplatin
159
Paclitaxel
153
Gemcitabine
153
Pemetrexed
122
Bevacizumab
121
Docetaxel
105
durvalumab
83
Oxaliplatin
82
Nivolumab
82
Dexamethasone
80
atezolizumab
79
Fluorouracil
79
Cyclophosphamide
79
130-nm albumin-bound paclitaxel
74
Fulvestrant
72
Capecitabine
67
Injections
66
Cetuximab
64
Leucovorin
63
Rituximab
57
fludarabine
52
Lenalidomide
51
venetoclax
47
Prednisone
45
Irinotecan
42
enzalutamide
41
Letrozole
41
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diphenhydramine
×
90 days
×
Clear all
NCT07570173
2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts